GlassScriptPhysician profile
Xuezhong Yang
NPI 1598922650
$1,483.29
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $41.48 · 2021: $25.06 · 2022: $76.28 · 2023: $367 · 2024: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.20 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $280.52 | 2023-2024 | Clonoseq |
| Astellas Pharma US INC | $254.36 | 2019 | |
| Genzyme Corporation | $120.05 | 2019-2023 | |
| Taiho Oncology, INC. | $93.32 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $84.36 | 2019-2022 | |
| Pfizer INC. | $73.05 | 2019-2021 | |
| Boston Scientific Corporation | $63.37 | 2024 | Therasphere Administration Set |
| Incyte Corporation | $60.14 | 2019-2023 | Jakafi, Pemazyre, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $51.97 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $46.40 | 2019 | |
| Tersera Therapeutics LLC | $43.48 | 2019 | |
| Amgen INC. | $35.86 | 2019-2022 | |
| Celgene Corporation | $31.66 | 2023 | Pomalyst, Opdualag |
| Genentech USA, INC. | $28.30 | 2019-2022 | |
| Servier Pharmaceuticals LLC | $24.75 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $23.85 | 2019 | |
| Acrotech Biopharma INC. | $22.75 | 2023 | Beleodaq |
| Abbvie INC. | $21.45 | 2023 | Venclexta |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Clovis Oncology, INC. | $20.64 | 2019-2020 | |
| Verastem, INC. | $15.97 | 2019 | |
| Secura Bio, INC. | $15.06 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.03 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.31 | 2019 | |
| Janssen Biotech, INC. | $11.28 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xuezhong Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.